Bone Therapeutics Treats First Patient in ALLOB Phase IIb Tibial Fracture Study

Bone Therapeutics announced it has treated the first patient for the ALLOB Phase IIb clinical study in patients with difficult-to-heal tibial fractures. The successful completion of Bone Therapeutics’ ALLOB trials would further demonstrate the promise of mesenchymal stromal derived cell therapies for the treatment of other underserved conditions.
[Bone Therapeutics]
Press Release
Bookmark

No account yet? Register

0
Share

Defining Human Mesenchymal and Epithelial Heterogeneity in Response to Oral Inflammatory Disease

Using single-cell transcriptome profiling, scientists reveal a striking remodelling of the epithelial and mesenchymal niches with a decrease in functional populations that are linked to the aetiology of chronic inflammatory disease.
[eLife]
Caetano, A. J., Yianni, V., Volponi, A., Booth, V., D’Agostino, E. M., & Sharpe, P. (2021). Defining human mesenchymal and epithelial heterogeneity in response to oral inflammatory disease. ELife, 10, e62810. https://doi.org/10.7554/eLife.62810 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Feasibility of Reduced-Dose Posttransplant Cyclophosphamide and Cotransplantation of Peripheral Blood Stem Cells and Umbilical Cord-Derived Mesenchymal Stem Cells for SAA

Scientists evaluated the effectiveness and safety of reduced-dose cyclophosphamide, 20 mg/kg for 13 patients in matched sibling donor hematopoietic stem cell transplantation (HSCT) cohort and 25 mg/kg for 22 patients in haplo-HSCT cohort, on days +3, +4 combined with cotransplantation of peripheral blood stem cells and human umbilical cord-derived MSCs for severe aplastic anemia (SAA).
[Scientific Reports]
Zu, Y., Zhou, J., Fu, Y., Fang, B., Liu, X., Zhang, Y., Yu, F., Zuo, W., Zhou, H., Gui, R., Li, Z., Liu, Y., Zhao, H., Zhang, C., & Song, Y. (2021). Feasibility of reduced-dose posttransplant cyclophosphamide and cotransplantation of peripheral blood stem cells and umbilical cord-derived mesenchymal stem cells for SAA. Scientific Reports, 11(1), 253. https://doi.org/10.1038/s41598-020-80531-7 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Extracellular Vesicle-Associated Repetitive Element DNAs As Candidate Osteosarcoma Biomarkers

Osteosarcoma (OS) is the most common malignant bone tumor in children and young adults. Despite high-risk factors being identified, no test for early detection is available. This study aimed to identify circulating nucleic acid sequences associated with serum extracellular vesicle preparations at the time of OS diagnosis, as a step towards an OS early detection assay.
[Scientific Reports]
Cambier, L., Stachelek, K., Triska, M., Jubran, R., Huang, M., Li, W., Zhang, J., Li, J., & Cobrinik, D. (2021). Extracellular vesicle-associated repetitive element DNAs as candidate osteosarcoma biomarkers. Scientific Reports, 11(1), 94. https://doi.org/10.1038/s41598-020-77398-z Cite
Full Article
Bookmark

No account yet? Register

0
Share

YAP/TAZ Inhibition Reduces Metastatic Potential of Ewing Sarcoma Cells

Investigators suggest that YAP/TAZ pathway inhibition may prevent Ewing sarcoma (EwS) cell dissemination and metastasis, justifying further preclinical development of YAP/TAZ inhibitors for EwS treatment.
[Oncogenesis]
Bierbaumer, L., Katschnig, A. M., Radic-Sarikas, B., Kauer, M. O., Petro, J. A., Högler, S., Gurnhofer, E., Pedot, G., Schäfer, B. W., Schwentner, R., Mühlbacher, K., Kromp, F., Aryee, D. N. T., Kenner, L., Uren, A., & Kovar, H. (2021). YAP/TAZ inhibition reduces metastatic potential of Ewing sarcoma cells. Oncogenesis, 10(1), 1–13. https://doi.org/10.1038/s41389-020-00294-8 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Microvascular Density, Endothelial Area, and Ki-67 Proliferative Index Correlate Each Other in Cat Post-Injection Fibrosarcoma

Scientists conducted a crossing study evaluating microvascular density, endothelial area, and Ki-67 proliferative index was reported for a series of formalin-fixed and paraffin-embedded tissue samples from 99 cat patients, affected by cat post-injection fibrosarcoma, by using a till ×400 magnification light microscopy.
[Cells]
Patruno, R., Passantino, G., Laface, C., Tinelli, A., Zito, A., Ruggieri, R., Luposella, F., Gadaleta, P., Laforgia, M., Lacitignola, L., Ammendola, M., Ranieri, G., & Zizzo, N. (2021). Microvascular Density, Endothelial Area, and Ki-67 Proliferative Index Correlate Each Other in Cat Post-Injection Fibrosarcoma. Cells, 10(1), 31. https://doi.org/10.3390/cells10010031 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Adiponectin Signaling in Bone Homeostasis, with Age and in Disease

The authors explore the current literature on adiponectin in bone, looking in depth at the comparison between human and murine data in health, with age and in disease.
[Bone Research]
Lewis, J. W., Edwards, J. R., Naylor, A. J., & McGettrick, H. M. (2021). Adiponectin signalling in bone homeostasis, with age and in disease. Bone Research, 9(1), 1–11. https://doi.org/10.1038/s41413-020-00122-0 Cite
Full Article
Bookmark

No account yet? Register

0
Share

HUCMSCs Transplantation Combined with Ultrashort Wave Therapy Attenuates Neuroinflammation in Spinal Cord Injury through NUR77/ NF-κB Pathway

Low-dose Ultrashort Wave was treated one day after spinal cord injury (SCI) and human umbilical cord mesenchymal stem cell suspension was transferred to the lesion using a micro-syringe seven days after SCI.
[Life Sciences]
Wang, S., Jia, Y., Cao, X., Feng, S., Na, L., Dong, H., Gao, J., & Zhang, L. (2020). HUCMSCs transplantation combined with ultrashort wave therapy attenuates neuroinflammation in spinal cord injury through NUR77/ NF-κB pathway. Life Sciences, 118958. https://doi.org/10.1016/j.lfs.2020.118958 Cite
Abstract
Bookmark

No account yet? Register

0
Share

Umbilical Cord Mesenchymal Stem Cells for COVID-19 Acute Respiratory Distress Syndrome: A Double-Blind, Phase I/IIa, Randomized Controlled Trial

Scientists determined the safety and explored efficacy of umbilical cord mesenchymal stem cell infusions in subjects with COVID‐19 scute respiratory distress syndrome. A double‐blind, Phase I/IIa, randomized, controlled trial was performed.
[Stem Cells Translational Medicine]
Lanzoni, G., Linetsky, E., Correa, D., Cayetano, S. M., Alvarez, R. A., Kouroupis, D., Gil, A. A., Poggioli, R., Ruiz, P., Marttos, A. C., Hirani, K., Bell, C. A., Kusack, H., Rafkin, L., Baidal, D., Pastewski, A., Gawri, K., Leñero, C., Mantero, A. M. A., … Ricordi, C. (n.d.). Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1/2a, randomized controlled trial. STEM CELLS Translational Medicine, n/a(n/a). https://doi.org/https://doi.org/10.1002/sctm.20-0472 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Olfactory Ecto-Mesenchymal Stem Cell-Derived Exosomes Ameliorate Murine Sjögren’s Syndrome by Modulating the Function of Myeloid-Derived Suppressor Cells

Scientists found that murine olfactory ecto-MSC-derived exosomes significantly enhanced the suppressive function of myeloid-derived suppressor cells by upregulating arginase expression and increasing ROS and NO levels.
[Cellular & Molecular Immunology]
Rui, K., Hong, Y., Zhu, Q., Shi, X., Xiao, F., Fu, H., Yin, Q., Xing, Y., Wu, X., Kong, X., Xu, H., Tian, J., Wang, S., & Lu, L. (2021). Olfactory ecto-mesenchymal stem cell-derived exosomes ameliorate murine Sjögren’s syndrome by modulating the function of myeloid-derived suppressor cells. Cellular & Molecular Immunology, 1–12. https://doi.org/10.1038/s41423-020-00587-3 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Transcriptional Activators YAP/TAZ and AXL Orchestrate Dedifferentiation, Cell Fate, and Metastasis in Human Osteosarcoma

To identify key drivers of metastasis, scientists studied human CCH-OS-D osteocarcinoma cells within a previously described rat acellular lung model that preserved the native lung architecture, extracellular matrix, and capillary network.
[Cancer Gene Therapy]
Lamhamedi-Cherradi, S.-E., Mohiuddin, S., Mishra, D. K., Krishnan, S., Velasco, A. R., Vetter, A. M., Pence, K., McCall, D., Truong, D. D., Cuglievan, B., Menegaz, B. A., Utama, B., Daw, N. C., Molina, E. R., Zielinski, R. J., Livingston, J. A., Gorlick, R., Mikos, A. G., Kim, M. P., & Ludwig, J. A. (2021). Transcriptional activators YAP/TAZ and AXL orchestrate dedifferentiation, cell fate, and metastasis in human osteosarcoma. Cancer Gene Therapy, 1–14. https://doi.org/10.1038/s41417-020-00281-6 Cite
Full Article
Bookmark

No account yet? Register

0
Share
Share